

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the below date: Date: July 21,2005

Name: John Murray, Ph.D.

Signature:

BRINKS HOFER GILSON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In re Appln. of: Charkrabarty et al.								FICE	&LIONE	
Appln. No.: 10/720,603							Examir	ner:	N/A	
Filed: November 24, 2003							Art U	nit:	N/A	
For: Cytotoxic Factors For Modulating Cell Death										
Attorney Docket No: 11472/11										
Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 TRANSMITTAL										
Sir:										
Attached is/are: Second Supplemental Information Disclosure Statement, Form PTO 1449 with references Return Receipt Postcard Fee calculation: No additional fee is required. Small Entity. An extension fee in an amount of \$ for amonth extension of time under 37 C.F.R. § 1.136(a). A petition or processing fee in an amount of \$ under 37 C.F.R. § 1.17(). An additional filing fee has been calculated as shown below:								§ 1.136(a).		
	Claims Re			Highest No. Previously Paid For	Present Extra	Rate	Add'l Fee	٥٢	Rate	Add'i Fee
Total	7.1.01 74110		Minus	. Toviously Falu i Ol	EAUG.	x \$25=	Addirec	or	x \$50=	Add 11 ce
Indep.			Minus			x 100=			x \$200=	
First P	resentation of I	Multiple De	p. Claim			+\$180=			+ \$360=	
						Total	\$		Total	\$
	for this purpose.								tal is enclosed	
Payment by credit card in the amount of \$ (Form PTO-2038 is attached). The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Director is hereby authorized to ensure that this paper is timely filed).								r (including any		

July 21, 2005

Account No. 23-1925.

Respectfully submitted,

I hereby county that this correspondence is being deposited with the inited States Postal Service, with sufficient commissioner for Patents

P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

on July 21, 2005
Date of Deposit

John Murray

Name of applicant, assignee or Registered Representative

Signature

ate of Signature

Our Case No. 11472/11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Charkrabarty et al.

Serial No.: 10/720,603

Filing Date: November 24, 2003

For: Cytotoxic Factors For Modulating

Cell Death

Examiner: Not assigned

Group Art Unit No.: Not Assigned

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is believed to be filed before the mailing of the first Office Action on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

This application claims benefit of provisional application number 60/414,550, filed August 15, 2003, and is a continuation-in-part of U.S. Patent Application Serial Number 10/047,710, filed January 15, 2002, which claims benefit of provisional application U.S. Ser. No. 60/269,133, filed February 15, 2001. These prior applications are relied upon for an earlier filing dated under 35 U.S.C. §§ 119 and 120. The following documents are cited:

US 5,681,810	Oct 28, 1997	Villemez et al.
US5,972,899	Oct 26, 1999	Zychlinsky et al.

Vasu Punj et al., "Bacterial Cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer", Oncogene (2004) 23, 2367-78.

Voet et al., (Biochemistry, 1990, John Wiley & Jons, pp. 415-17, 932 and 933)

Definition of "necrosis" as "to make dead" according to Merriam-Webster Online dictionary downloaded from URL>>www.m-w.com on 4/25/2005

Applicants are enclosing Form PTO-1449 (one sheet), along with a copy of each listed non U.S. patent reference for which a copy is required under 37 C.F.R. §1.98(a)(2).

If, for any reason, the Examiner feels that an interview would be helpful to resolve any issues, he is respectfully requested to contact the undersigned attorney at (312) 321-4229.

Respectfully submitted,

Date: July 21, 2005

John Murray, Ph.D. Registration No. 44,251

Attorney for Applicant

BRINKS HOFER GILSON & LIONE P.O. Box 10395 Chicago, IL 60610 (312) 321-4200

FORM PTO-1449	SERIAL NO.	CASE NO.
MADE	10/720.603	11472/11
LIST OF PATENTS AND PUBLICATIONS FOR	FILING DATE	GROUP ART UNIT
APPLICANT'S INFORMATION DISCLOSURE	November 24, 2003	Not Assigned
STATEMENT		
(use several sheets if necessary)	APPLICANT(S): Das Gupta et a	I.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	C1	US 5,681,810	Oct 28, 1997	Villemez et al.		
	C2	US5,972,899	Oct 26, 1999	Zychlinsky et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANS YES	LATION NO

EXAMINER INITIAL		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
	C3	Vasu Punj et al., "Bacterial Cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer", Oncogene (2004) 23, 2367-78.
	C4	Voet et al., (Biochemistry, 1990, John Wiley & Jons, pp. 415-17, 932 and 933)
	C5	Definition of "necrosis" as "to make dead" according to Merriam-Webster Online dictionary downloaded from URL>>www.m-w.com on 4/25/2005

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.